ClinicalTrials.gg
CompletedNCT05422976Updated Jul 21, 2023

EVI-01-IT Safety Study

An interventional study of EVI-01 in Knee Osteoarthritis, sponsored by Aptissen SA. Completed at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-07-21.

Sponsored by Aptissen SA · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
24
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 106 studies in Osteoarthritis, Knee with a site in Italy — 29 open to participants now, 33 under way, 3 of them phase 3. Osteoarthritis, Knee · Italy.

Enrollment
75th of 84
24 · median 65
Started
2022
with 7 others
No phase
59 of 106
18 open now
Registered
61st of 106
by date

Among the 106 studies in Osteoarthritis, Knee with a site in Italy, this one is the 75th largest by enrollment of the 84 interventional ones that give a count, is one of 8 that started in 2022, is one of 59 with no phase, and was the 61st registered.

Osteoarthritis, Knee

3,297 studies on the registry are indexed under Osteoarthritis, Knee; 623 are open to participants now.

Browse Osteoarthritis, Knee studies →

Open to participants now

29 of the 106 studies in Osteoarthritis, Knee with a site in Italy are open now. Recruiting first, the newest first:

24 more — sign in →

All 29 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 384 Osteoarthritis, Knee studies recruiting now, 178 (46%) set no upper age limit and 113 (29%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 106 studies in Osteoarthritis, Knee with a site in Italy, or all of them as a file.
02

Study summary

Prospective, single arm, pilot study to assess the safety and tolerability of a single intra-articular injection of EVI-01 for the treatment of symptomatic knee osteoarthritis.

03

Conditions studied

  • Knee Osteoarthritis

Keywords

  • highly concentrated hyaluronic acid
  • knee osteoarthritis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Eighteen (18) years old or above;
  • Patient signed form;
  • Patients with stable symptoms related to knee osteoarthritis for at least 3 months prior to screening;
  • Failure, inadequate response or intolerance to analgesics and/or NSAIDs or low-grade opioids;
  • Kellgren-Lawrence radiographic stage: II-III diagnosed in the previous 12 months;
  • WOMAC average pain index score > 40 mm and \< 90 (on a VAS 0-100 mm) on the knee to be treated;
  • Difference ≥ 10 mm between the WOMAC average pain score of the knee to be treated and WOMAC average pain score of the contralateral knee at screening;
  • (BMI) inferior to 35 kg/m2 (weight/height).

Exclusion criteria

Exclusion Criteria:

  • Concomitant inflammatory joint disorder;
  • Had received previous visco-supplementation treatment in the study knee within 6 months or intra articular within 3 months* prior to inclusion;
  • Infection in or around the study knee;
  • Relevant skin disease in the area of injection site;
  • Documented presence of injury or trauma of the study knee at screening, including evidence of a subchondral fracture, meniscal lesion, presence of bone or cartilage fragments in the study knee;
  • History of allergy or intolerance to sodium hyaluronate;
  • Documented presence of osteonecrosis in one or both knees;
  • Inability to understand the study procedure;
  • Participation in another clinical trial within 30 days prior to screening;
  • Ongoing therapy with daily dosage > 101 mg of acetylsalicylic acid as part of cardiovascular preventive treatment. If dose \< 101 mg, it must be maintained during the study;
  • Pregnant or breast-feeding at inclusion.

    • 1 month = 30 days
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    EVI-01 treatment

    EVI-01 should be injected within the synovial cavity using standard procedures for intra-articular (IA) injections by a physician skilled in performing IA injections.

    Device: EVI-01

Interventions

  • DeviceEVI-01

    High molecular weight Hyaluronic Acid

06

What researchers measure

Primary outcomes

  1. Safety and tolerability

    Primary objective of this study is to assess the safety and tolerability of EVI-01 following single intraarticular administration in the knee joint, assessed with adverse events monitoring throughout the follow up duration of six months.

    Time frame: 6 months

Secondary outcomes

  1. Change in patient-reported pain intensity

    Change in patient-reported pain intensity at Days 1 to 7 compared to baseline will be assess using a 0-100 mm Visual Analogue Scale (VAS), in which 0 means ''no pain at all'' and 100 means ''the worst possible pain''.

    Time frame: 7 days

  2. Change in WOMAC index

    The Western Ontario and McMaster Universities Arthritis Index (WOMAC) consists of a total of 24 questions divided in 5 questions related to pain, 2 questions related to stiffness and 17 questions related to difficulties in performing activities of daily living in relation to physical function. Each question refers to a 0-100 mm Visual Analogue Scale (VAS) in which 0 means ''no pain at all'' and 100 means ''the worst possible pain''. Change in WOMAC pain, stiffness, function and total score will be assess using WOMAC index at Day 7, Day 14, Day 30, Day 90 and Day 180 compared to baseline

    Time frame: 6 months

  3. Patient satisfaction for the overall treatment effect

    Measurements of relief satisfaction by the patient will be assess using a 7 points Likert scale at Day 180. A 7 point Likert scale offers 7 different answer options related to an agreement that would be distinct enough for the respondents (Very good, Good, Fairly good, Same as before, Fairly bad, Bad, Very bad).

    Time frame: 6 months

  4. Physician satisfaction for the overall treatment effect

    Measurements of relief satisfaction by the physician will be assess using a 7 points Likert scale at Day 180. A 7 point Likert scale offers 7 different answer options related to an agreement that would be distinct enough for the respondents (Very good, Good, Fairly good, Same as before, Fairly bad, Bad, Very bad).

    Time frame: 6 months

07

Study locations

1 site
  • IRCCS Istituto Ortopedico Rizzoli
    Bologna, 40136, Italy
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2022 to primary completion in May 2023, 11 months.

Of 139 industry-sponsored interventional studies with no phase under Osteoarthritis, Knee, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 34. This study's 11 months is below that.

Counting every sponsor, half of 1,253 studies reached it within 18 months; a quarter within 8 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 7, 2022
First posted
Jun 21, 2022
StartActual
Jun 23, 2022
Primary completionActual
May 31, 2023
CompletionActual
May 31, 2023
Last update
Jul 21, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 21, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05422976
Lead sponsor
Aptissen SA
Collaborators
Donawa Lifescience
Responsible party
Sponsor
First posted
Jun 21, 2022
Start date
Jun 23, 2022
Primary completion
May 31, 2023
Completion
May 31, 2023
Last update
Jul 21, 2023

Study contacts

Stefano Zaffagnini, MD
principal investigator · IRCCS Istituto Ortopedico Rizzoli

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion